Immunome Inc. (IMNM): Price and Financial Metrics

Immunome Inc. (IMNM): $23.25

1.24 (+5.63%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add IMNM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#78 of 356

in industry

IMNM Price/Volume Stats

Current price $23.25 52-week high $26.84
Prev. close $22.01 52-week low $4.04
Day low $22.20 Volume 563,500
Day high $23.87 Avg. volume 759,386
50-day MA $14.90 Dividend yield N/A
200-day MA $9.12 Market Cap 1.27B

IMNM Stock Price Chart Interactive Chart >

IMNM POWR Grades

  • Growth is the dimension where IMNM ranks best; there it ranks ahead of 92.26% of US stocks.
  • IMNM's strongest trending metric is Stability; it's been moving up over the last 26 weeks.
  • IMNM's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).

IMNM Stock Summary

  • Price to trailing twelve month operating cash flow for IMNM is currently 157.31, higher than 98.06% of US stocks with positive operating cash flow.
  • For IMNM, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
  • Revenue growth over the past 12 months for IMMUNOME INC comes in at 331.13%, a number that bests 98.31% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IMNM, based on their financial statements, market capitalization, and price volatility, are RYTM, AIP, TFFP, TDUP, and LCID.
  • Visit IMNM's SEC page to see the company's official filings. To visit the company's web site, go to immunome.com.

IMNM Valuation Summary

  • IMNM's price/sales ratio is 44.9; this is 969.05% higher than that of the median Healthcare stock.
  • IMNM's price/sales ratio has moved NA NA over the prior 39 months.

Below are key valuation metrics over time for IMNM.

Stock Date P/S P/B P/E EV/EBIT
IMNM 2023-12-29 44.9 75.2 -20.8 -16.7
IMNM 2023-12-28 45.0 75.5 -20.9 -16.7
IMNM 2023-12-27 43.5 73.0 -20.2 -16.1
IMNM 2023-12-26 42.6 71.4 -19.8 -15.6
IMNM 2023-12-22 39.4 66.0 -18.3 -14.1
IMNM 2023-12-21 35.0 58.8 -16.3 -12.1

IMNM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IMNM has a Quality Grade of D, ranking ahead of 16.22% of graded US stocks.
  • IMNM's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows IMNM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -15.443
2020-12-31 0 NA -10.028

IMNM Price Target

For more insight on analysts targets of IMNM, see our IMNM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.00 Average Broker Recommendation 1 (Strong Buy)

Immunome Inc. (IMNM) Company Bio


Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.


IMNM Latest News Stream


Event/Time News Detail
Loading, please wait...

IMNM Latest Social Stream


Loading social stream, please wait...

View Full IMNM Social Stream

Latest IMNM News From Around the Web

Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.

Immunome to Present at the Stifel 2023 Healthcare Conference

SEATTLE & EXTON, Pa., November 10, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Yahoo | November 10, 2023

Immunome Reports Third Quarter 2023 Financial Results

SEATTLE & EXTON, Pa., November 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 9, 2023

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

SEATTLE & EXTON, Pa., November 08, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.

Yahoo | November 8, 2023

7 Biotech Stocks to Get In Now Before Investors Catch On

Biotech stocks are down, but there are hidden gems among the rubble.

John Blankenhorn on InvestorPlace | October 23, 2023

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

SEATTLE & EXTON, Pa., October 19, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.

Yahoo | October 19, 2023

Read More 'IMNM' Stories Here

IMNM Price Returns

1-mo 51.76%
3-mo 190.63%
6-mo 271.41%
1-year 361.31%
3-year -18.45%
5-year N/A
YTD 117.29%
2023 384.16%
2022 -82.95%
2021 33.88%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!